medigraphic.com
ISSN 0210-5187 (Electronic)

2008, Number 2

<< Back Next >>

Med Cutan Iber Lat Am 2008; 36 (2)

Systemic amyloidosis multiple myeloma-associated

João A, Serrano P, Bártolo E, Neves A, Menezes BF

Language: Portugués
References: 11
Page: 84-87
PDF size: 239.59 Kb.


Text Extraction

AL amyloidosis results from tissue deposition of immunoglobulin light chains, occurring in 15% of patients with multiple myeloma. Mucocutaneous lesions are often the first manifestations, helping in earlier recognition of monoclonal gamapathy.
A 71-year-old man who with cutaneous lesions on the eyelids, retroauricular folds and upper back, which proved to be due to amyloid deposition is reported. Further investigation revealed multiple myeloma.


REFERENCES

  1. 1.Glenner GG. Amyloid deposits and amyloidosis. The B-fibrilloses. N Engl J Med 1980;302:1283-92.

  2. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol 1988;18:1-16.

  3. 3.Falk RH, Comenzo RL, Skinner M. The Systemic Amyloidosis. N Engl J Med 1997;25:898-908.

  4. Kois JM, Sexton FM, Lookingbill. Cutaneous Manifestations of Multiple Myeloma. Arch Dermatol 1991;127:69-74.

  5. 5.Gutiérrez JV, Fernández MM, Sambucety PS, Valiente JS, Prieto MA. Med Cutan Iber Lat Am 2004;32:211-214.

  6. 6.Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins: preferential association of the V λ VI subgroup of human light chains with amyloidosis AL (l). J Clin Invest 1982;70:453-60.

  7. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.

  8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.

  9. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.

  10. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for treatment of AL amyloidosis: one year follow-up in five patients. Blood 1996;88:2801-6.

  11. Dubrey SW, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996;125:481-4.




2020     |     www.medigraphic.com